COVID-19 Impact on Global Targeted Drugs for Multiple Myeloma Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-targeted-drugs-4-multiple-myeloma-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global Targeted Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Celgene
- Exova
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
- J&J
- Takeda
- Amgen
- Bristol Myers Squibb
- Abbvie
- Seattle Genetics
- Karyopharm Therapeutics
- PDL BioPharma
- Roche
- Sumitomo
- Merck
- Biogen
- Schering-Plough
- Glaxo
- Chiron
- Immunomodulator
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors (HDACI)
- Monoclonal Antibody
- Other
- Hospital
- Drug Center
- Clinic
- Other
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Targeted Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.
- To present the Targeted Drugs for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
1.4 Market Analysis by Type
1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Immunomodulator
1.4.3 Proteasome Inhibitors
1.4.4 Histone Deacetylase Inhibitors (HDACI)
1.4.5 Monoclonal Antibody
1.4.6 Other
1.5 Market by Application
1.5.1 Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Drug Center
1.5.4 Clinic
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for Multiple Myeloma Industry Impact
1.6.1 How the Covid-19 is Affecting the Targeted Drugs for Multiple Myeloma Industry
1.6.1.1 Targeted Drugs for Multiple Myeloma Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Targeted Drugs for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Targeted Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Targeted Drugs for Multiple Myeloma Market Perspective (2015-2026)
2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Regions
2.2.1 Targeted Drugs for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Share by Regions (2015-2020)
2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Targeted Drugs for Multiple Myeloma Market Growth Strategy
2.3.6 Primary Interviews with Key Targeted Drugs for Multiple Myeloma Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Market Size
3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2015-2020)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2015-2020)
3.1.3 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
3.2.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2019
3.3 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
3.4 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
3.5 Date of Enter into Targeted Drugs for Multiple Myeloma Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2021-2026)
5 TARGETED DRUGS FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
6.2 Targeted Drugs for Multiple Myeloma Key Players in North America (2019-2020)
6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
7.2 Targeted Drugs for Multiple Myeloma Key Players in Europe (2019-2020)
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
8 CHINA
8.1 China Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
8.2 Targeted Drugs for Multiple Myeloma Key Players in China (2019-2020)
8.3 China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
8.4 China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
9.2 Targeted Drugs for Multiple Myeloma Key Players in Japan (2019-2020)
9.3 Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
9.4 Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
10.2 Targeted Drugs for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
11 INDIA
11.1 India Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
11.2 Targeted Drugs for Multiple Myeloma Key Players in India (2019-2020)
11.3 India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
11.4 India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
12.2 Targeted Drugs for Multiple Myeloma Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Celgene
13.1.1 Celgene Company Details
13.1.2 Celgene Business Overview and Its Total Revenue
13.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
13.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020))
13.1.5 Celgene Recent Development
13.2 Exova
13.2.1 Exova Company Details
13.2.2 Exova Business Overview and Its Total Revenue
13.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction
13.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.2.5 Exova Recent Development
13.3 Natco Pharma
13.3.1 Natco Pharma Company Details
13.3.2 Natco Pharma Business Overview and Its Total Revenue
13.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction
13.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.3.5 Natco Pharma Recent Development
13.4 Intas Pharmaceuticals
13.4.1 Intas Pharmaceuticals Company Details
13.4.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
13.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
13.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.4.5 Intas Pharmaceuticals Recent Development
13.5 Indiabulls Pharmaceutical
13.5.1 Indiabulls Pharmaceutical Company Details
13.5.2 Indiabulls Pharmaceutical Business Overview and Its Total Revenue
13.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
13.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.5.5 Indiabulls Pharmaceutical Recent Development
13.6 Cipla
13.6.1 Cipla Company Details
13.6.2 Cipla Business Overview and Its Total Revenue
13.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction
13.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.6.5 Cipla Recent Development
13.7 Glenmark Pharmaceuticals
13.7.1 Glenmark Pharmaceuticals Company Details
13.7.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
13.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.7.5 Glenmark Pharmaceuticals Recent Development
13.8 Dr Reddy's Laboratories
13.8.1 Dr Reddy's Laboratories Company Details
13.8.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue
13.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction
13.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.8.5 Dr Reddy's Laboratories Recent Development
13.9 Qilu Pharmaceutical
13.9.1 Qilu Pharmaceutical Company Details
13.9.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
13.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
13.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.9.5 Qilu Pharmaceutical Recent Development
13.10 Chia Tai-Tianqing
13.10.1 Chia Tai-Tianqing Company Details
13.10.2 Chia Tai-Tianqing Business Overview and Its Total Revenue
13.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction
13.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.10.5 Chia Tai-Tianqing Recent Development
13.11 Hanson Pharm
10.11.1 Hanson Pharm Company Details
10.11.2 Hanson Pharm Business Overview and Its Total Revenue
10.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction
10.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.11.5 Hanson Pharm Recent Development
13.12 Meidakang Huakang Pharmaceutical
10.12.1 Meidakang Huakang Pharmaceutical Company Details
10.12.2 Meidakang Huakang Pharmaceutical Business Overview and Its Total Revenue
10.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
10.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.12.5 Meidakang Huakang Pharmaceutical Recent Development
13.13 Shandong Kongfu Pharmaceutical
10.13.1 Shandong Kongfu Pharmaceutical Company Details
10.13.2 Shandong Kongfu Pharmaceutical Business Overview and Its Total Revenue
10.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
10.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.13.5 Shandong Kongfu Pharmaceutical Recent Development
13.14 J&J
10.14.1 J&J Company Details
10.14.2 J&J Business Overview and Its Total Revenue
10.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
10.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.14.5 J&J Recent Development
13.15 Takeda
10.15.1 Takeda Company Details
10.15.2 Takeda Business Overview and Its Total Revenue
10.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
10.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.15.5 Takeda Recent Development
13.16 Amgen
10.16.1 Amgen Company Details
10.16.2 Amgen Business Overview and Its Total Revenue
10.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
10.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.16.5 Amgen Recent Development
13.17 Bristol Myers Squibb
10.17.1 Bristol Myers Squibb Company Details
10.17.2 Bristol Myers Squibb Business Overview and Its Total Revenue
10.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
10.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.17.5 Bristol Myers Squibb Recent Development
13.18 Abbvie
10.18.1 Abbvie Company Details
10.18.2 Abbvie Business Overview and Its Total Revenue
10.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
10.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.18.5 Abbvie Recent Development
13.19 Seattle Genetics
10.19.1 Seattle Genetics Company Details
10.19.2 Seattle Genetics Business Overview and Its Total Revenue
10.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
10.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.19.5 Seattle Genetics Recent Development
13.20 Karyopharm Therapeutics
10.20.1 Karyopharm Therapeutics Company Details
10.20.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
10.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
10.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.20.5 Karyopharm Therapeutics Recent Development
13.21 PDL BioPharma
10.21.1 PDL BioPharma Company Details
10.21.2 PDL BioPharma Business Overview and Its Total Revenue
10.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
10.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.21.5 PDL BioPharma Recent Development
13.22 Roche
10.22.1 Roche Company Details
10.22.2 Roche Business Overview and Its Total Revenue
10.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
10.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.22.5 Roche Recent Development
13.23 Sumitomo
10.23.1 Sumitomo Company Details
10.23.2 Sumitomo Business Overview and Its Total Revenue
10.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
10.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.23.5 Sumitomo Recent Development
13.24 Merck
10.24.1 Merck Company Details
10.24.2 Merck Business Overview and Its Total Revenue
10.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction
10.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.24.5 Merck Recent Development
13.25 Biogen
10.25.1 Biogen Company Details
10.25.2 Biogen Business Overview and Its Total Revenue
10.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction
10.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.25.5 Biogen Recent Development
13.26 Schering-Plough
10.26.1 Schering-Plough Company Details
10.26.2 Schering-Plough Business Overview and Its Total Revenue
10.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction
10.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.26.5 Schering-Plough Recent Development
13.27 Glaxo
10.27.1 Glaxo Company Details
10.27.2 Glaxo Business Overview and Its Total Revenue
10.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction
10.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.27.5 Glaxo Recent Development
13.28 Chiron
10.28.1 Chiron Company Details
10.28.2 Chiron Business Overview and Its Total Revenue
10.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction
10.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.28.5 Chiron Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
1.4 Market Analysis by Type
1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Immunomodulator
1.4.3 Proteasome Inhibitors
1.4.4 Histone Deacetylase Inhibitors (HDACI)
1.4.5 Monoclonal Antibody
1.4.6 Other
1.5 Market by Application
1.5.1 Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Drug Center
1.5.4 Clinic
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for Multiple Myeloma Industry Impact
1.6.1 How the Covid-19 is Affecting the Targeted Drugs for Multiple Myeloma Industry
1.6.1.1 Targeted Drugs for Multiple Myeloma Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Targeted Drugs for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Targeted Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Targeted Drugs for Multiple Myeloma Market Perspective (2015-2026)
2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Regions
2.2.1 Targeted Drugs for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Share by Regions (2015-2020)
2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Targeted Drugs for Multiple Myeloma Market Growth Strategy
2.3.6 Primary Interviews with Key Targeted Drugs for Multiple Myeloma Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Market Size
3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2015-2020)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2015-2020)
3.1.3 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
3.2.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2019
3.3 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
3.4 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
3.5 Date of Enter into Targeted Drugs for Multiple Myeloma Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2015-2020)
4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2021-2026)
5 TARGETED DRUGS FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
6.2 Targeted Drugs for Multiple Myeloma Key Players in North America (2019-2020)
6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
7.2 Targeted Drugs for Multiple Myeloma Key Players in Europe (2019-2020)
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
8 CHINA
8.1 China Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
8.2 Targeted Drugs for Multiple Myeloma Key Players in China (2019-2020)
8.3 China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
8.4 China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
9.2 Targeted Drugs for Multiple Myeloma Key Players in Japan (2019-2020)
9.3 Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
9.4 Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
10.2 Targeted Drugs for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
10.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
11 INDIA
11.1 India Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
11.2 Targeted Drugs for Multiple Myeloma Key Players in India (2019-2020)
11.3 India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
11.4 India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
12.2 Targeted Drugs for Multiple Myeloma Key Players in Central & South America (2019-2020)
12.3 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
12.4 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Celgene
13.1.1 Celgene Company Details
13.1.2 Celgene Business Overview and Its Total Revenue
13.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
13.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020))
13.1.5 Celgene Recent Development
13.2 Exova
13.2.1 Exova Company Details
13.2.2 Exova Business Overview and Its Total Revenue
13.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction
13.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.2.5 Exova Recent Development
13.3 Natco Pharma
13.3.1 Natco Pharma Company Details
13.3.2 Natco Pharma Business Overview and Its Total Revenue
13.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction
13.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.3.5 Natco Pharma Recent Development
13.4 Intas Pharmaceuticals
13.4.1 Intas Pharmaceuticals Company Details
13.4.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
13.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
13.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.4.5 Intas Pharmaceuticals Recent Development
13.5 Indiabulls Pharmaceutical
13.5.1 Indiabulls Pharmaceutical Company Details
13.5.2 Indiabulls Pharmaceutical Business Overview and Its Total Revenue
13.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
13.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.5.5 Indiabulls Pharmaceutical Recent Development
13.6 Cipla
13.6.1 Cipla Company Details
13.6.2 Cipla Business Overview and Its Total Revenue
13.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction
13.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.6.5 Cipla Recent Development
13.7 Glenmark Pharmaceuticals
13.7.1 Glenmark Pharmaceuticals Company Details
13.7.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
13.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.7.5 Glenmark Pharmaceuticals Recent Development
13.8 Dr Reddy's Laboratories
13.8.1 Dr Reddy's Laboratories Company Details
13.8.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue
13.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction
13.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.8.5 Dr Reddy's Laboratories Recent Development
13.9 Qilu Pharmaceutical
13.9.1 Qilu Pharmaceutical Company Details
13.9.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
13.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
13.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.9.5 Qilu Pharmaceutical Recent Development
13.10 Chia Tai-Tianqing
13.10.1 Chia Tai-Tianqing Company Details
13.10.2 Chia Tai-Tianqing Business Overview and Its Total Revenue
13.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction
13.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
13.10.5 Chia Tai-Tianqing Recent Development
13.11 Hanson Pharm
10.11.1 Hanson Pharm Company Details
10.11.2 Hanson Pharm Business Overview and Its Total Revenue
10.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction
10.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.11.5 Hanson Pharm Recent Development
13.12 Meidakang Huakang Pharmaceutical
10.12.1 Meidakang Huakang Pharmaceutical Company Details
10.12.2 Meidakang Huakang Pharmaceutical Business Overview and Its Total Revenue
10.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
10.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.12.5 Meidakang Huakang Pharmaceutical Recent Development
13.13 Shandong Kongfu Pharmaceutical
10.13.1 Shandong Kongfu Pharmaceutical Company Details
10.13.2 Shandong Kongfu Pharmaceutical Business Overview and Its Total Revenue
10.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
10.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.13.5 Shandong Kongfu Pharmaceutical Recent Development
13.14 J&J
10.14.1 J&J Company Details
10.14.2 J&J Business Overview and Its Total Revenue
10.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
10.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.14.5 J&J Recent Development
13.15 Takeda
10.15.1 Takeda Company Details
10.15.2 Takeda Business Overview and Its Total Revenue
10.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
10.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.15.5 Takeda Recent Development
13.16 Amgen
10.16.1 Amgen Company Details
10.16.2 Amgen Business Overview and Its Total Revenue
10.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
10.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.16.5 Amgen Recent Development
13.17 Bristol Myers Squibb
10.17.1 Bristol Myers Squibb Company Details
10.17.2 Bristol Myers Squibb Business Overview and Its Total Revenue
10.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
10.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.17.5 Bristol Myers Squibb Recent Development
13.18 Abbvie
10.18.1 Abbvie Company Details
10.18.2 Abbvie Business Overview and Its Total Revenue
10.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
10.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.18.5 Abbvie Recent Development
13.19 Seattle Genetics
10.19.1 Seattle Genetics Company Details
10.19.2 Seattle Genetics Business Overview and Its Total Revenue
10.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
10.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.19.5 Seattle Genetics Recent Development
13.20 Karyopharm Therapeutics
10.20.1 Karyopharm Therapeutics Company Details
10.20.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
10.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
10.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.20.5 Karyopharm Therapeutics Recent Development
13.21 PDL BioPharma
10.21.1 PDL BioPharma Company Details
10.21.2 PDL BioPharma Business Overview and Its Total Revenue
10.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
10.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.21.5 PDL BioPharma Recent Development
13.22 Roche
10.22.1 Roche Company Details
10.22.2 Roche Business Overview and Its Total Revenue
10.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
10.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.22.5 Roche Recent Development
13.23 Sumitomo
10.23.1 Sumitomo Company Details
10.23.2 Sumitomo Business Overview and Its Total Revenue
10.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
10.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.23.5 Sumitomo Recent Development
13.24 Merck
10.24.1 Merck Company Details
10.24.2 Merck Business Overview and Its Total Revenue
10.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction
10.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.24.5 Merck Recent Development
13.25 Biogen
10.25.1 Biogen Company Details
10.25.2 Biogen Business Overview and Its Total Revenue
10.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction
10.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.25.5 Biogen Recent Development
13.26 Schering-Plough
10.26.1 Schering-Plough Company Details
10.26.2 Schering-Plough Business Overview and Its Total Revenue
10.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction
10.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.26.5 Schering-Plough Recent Development
13.27 Glaxo
10.27.1 Glaxo Company Details
10.27.2 Glaxo Business Overview and Its Total Revenue
10.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction
10.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.27.5 Glaxo Recent Development
13.28 Chiron
10.28.1 Chiron Company Details
10.28.2 Chiron Business Overview and Its Total Revenue
10.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction
10.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
10.28.5 Chiron Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Targeted Drugs for Multiple Myeloma Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
Table 3. Ranking of Global Top Targeted Drugs for Multiple Myeloma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Immunomodulator
Table 6. Key Players of Proteasome Inhibitors
Table 7. Key Players of Histone Deacetylase Inhibitors (HDACI)
Table 8. Key Players of Monoclonal Antibody
Table 9. Key Players of Other
Table 10. COVID-19 Impact Global Market: (Four Targeted Drugs for Multiple Myeloma Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Targeted Drugs for Multiple Myeloma Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Targeted Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
Table 15. Global Targeted Drugs for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Targeted Drugs for Multiple Myeloma Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Targeted Drugs for Multiple Myeloma Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2015-2020)
Table 19. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Targeted Drugs for Multiple Myeloma Market Growth Strategy
Table 25. Main Points Interviewed from Key Targeted Drugs for Multiple Myeloma Players
Table 26. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2015-2020) (Million US$)
Table 27. Global Targeted Drugs for Multiple Myeloma Market Share by Players (2015-2020)
Table 28. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019)
Table 29. Global Targeted Drugs for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
Table 32. Date of Enter into Targeted Drugs for Multiple Myeloma Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 35. Global Targeted Drugs for Multiple Myeloma Market Size Share by Type (2015-2020)
Table 36. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2021-2026)
Table 37. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application (2015-2020)
Table 38. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 39. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application (2021-2026)
Table 40. North America Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 42. North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 43. North America Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 44. North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 45. North America Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 46. Europe Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 48. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 50. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 52. China Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 53. China Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 54. China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 55. China Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 56. China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 57. China Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 58. Japan Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 60. Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 62. Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 68. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 70. India Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 71. India Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 72. India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 73. India Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 74. India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 75. India Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 78. Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 80. Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 82. Celgene Company Details
Table 83. Celgene Business Overview
Table 84. Celgene Product
Table 85. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 86. Celgene Recent Development
Table 87. Exova Company Details
Table 88. Exova Business Overview
Table 89. Exova Product
Table 90. Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 91. Exova Recent Development
Table 92. Natco Pharma Company Details
Table 93. Natco Pharma Business Overview
Table 94. Natco Pharma Product
Table 95. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 96. Natco Pharma Recent Development
Table 97. Intas Pharmaceuticals Company Details
Table 98. Intas Pharmaceuticals Business Overview
Table 99. Intas Pharmaceuticals Product
Table 100. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 101. Intas Pharmaceuticals Recent Development
Table 102. Indiabulls Pharmaceutical Company Details
Table 103. Indiabulls Pharmaceutical Business Overview
Table 104. Indiabulls Pharmaceutical Product
Table 105. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 106. Indiabulls Pharmaceutical Recent Development
Table 107. Cipla Company Details
Table 108. Cipla Business Overview
Table 109. Cipla Product
Table 110. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 111. Cipla Recent Development
Table 112. Glenmark Pharmaceuticals Company Details
Table 113. Glenmark Pharmaceuticals Business Overview
Table 114. Glenmark Pharmaceuticals Product
Table 115. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 116. Glenmark Pharmaceuticals Recent Development
Table 117. Dr Reddy's Laboratories Business Overview
Table 118. Dr Reddy's Laboratories Product
Table 119. Dr Reddy's Laboratories Company Details
Table 120. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 121. Dr Reddy's Laboratories Recent Development
Table 122. Qilu Pharmaceutical Company Details
Table 123. Qilu Pharmaceutical Business Overview
Table 124. Qilu Pharmaceutical Product
Table 125. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 126. Qilu Pharmaceutical Recent Development
Table 127. Chia Tai-Tianqing Company Details
Table 128. Chia Tai-Tianqing Business Overview
Table 129. Chia Tai-Tianqing Product
Table 130. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 131. Chia Tai-Tianqing Recent Development
Table 132. Hanson Pharm Company Details
Table 133. Hanson Pharm Business Overview
Table 134. Hanson Pharm Product
Table 135. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 136. Hanson Pharm Recent Development
Table 137. Meidakang Huakang Pharmaceutical Company Details
Table 138. Meidakang Huakang Pharmaceutical Business Overview
Table 139. Meidakang Huakang Pharmaceutical Product
Table 140. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 141. Meidakang Huakang Pharmaceutical Recent Development
Table 142. Shandong Kongfu Pharmaceutical Company Details
Table 143. Shandong Kongfu Pharmaceutical Business Overview
Table 144. Shandong Kongfu Pharmaceutical Product
Table 145. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 146. Shandong Kongfu Pharmaceutical Recent Development
Table 147. J&J Company Details
Table 148. J&J Business Overview
Table 149. J&J Product
Table 150. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 151. J&J Recent Development
Table 152. Takeda Company Details
Table 153. Takeda Business Overview
Table 154. Takeda Product
Table 155. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 156. Takeda Recent Development
Table 157. Amgen Company Details
Table 158. Amgen Business Overview
Table 159. Amgen Product
Table 160. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 161. Amgen Recent Development
Table 162. Bristol Myers Squibb Company Details
Table 163. Bristol Myers Squibb Business Overview
Table 164. Bristol Myers Squibb Product
Table 165. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 166. Bristol Myers Squibb Recent Development
Table 167. Abbvie Company Details
Table 168. Abbvie Business Overview
Table 169. Abbvie Product
Table 170. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 171. Abbvie Recent Development
Table 172. Seattle Genetics Company Details
Table 173. Seattle Genetics Business Overview
Table 174. Seattle Genetics Product
Table 175. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 176. Seattle Genetics Recent Development
Table 177. Karyopharm Therapeutics Company Details
Table 178. Karyopharm Therapeutics Business Overview
Table 179. Karyopharm Therapeutics Product
Table 180. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 181. Karyopharm Therapeutics Recent Development
Table 182. PDL BioPharma Company Details
Table 183. PDL BioPharma Business Overview
Table 184. PDL BioPharma Product
Table 185. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 186. PDL BioPharma Recent Development
Table 187. Roche Company Details
Table 188. Roche Business Overview
Table 189. Roche Product
Table 190. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 191. Roche Recent Development
Table 192. Sumitomo Company Details
Table 193. Sumitomo Business Overview
Table 194. Sumitomo Product
Table 195. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 196. Sumitomo Recent Development
Table 197. Merck Company Details
Table 198. Merck Business Overview
Table 199. Merck Product
Table 200. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 201. Merck Recent Development
Table 202. Biogen Company Details
Table 203. Biogen Business Overview
Table 204. Biogen Product
Table 205. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 206. Biogen Recent Development
Table 207. Schering-Plough Company Details
Table 208. Schering-Plough Business Overview
Table 209. Schering-Plough Product
Table 210. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 211. Schering-Plough Recent Development
Table 212. Glaxo Company Details
Table 213. Glaxo Business Overview
Table 214. Glaxo Product
Table 215. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 216. Glaxo Recent Development
Table 217. Chiron Company Details
Table 218. Chiron Business Overview
Table 219. Chiron Product
Table 220. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 221. Chiron Recent Development
Table 222. Research Programs/Design for This Report
Table 223. Key Data Information from Secondary Sources
Table 224. Key Data Information from Primary Sources
Table 1. Targeted Drugs for Multiple Myeloma Key Market Segments
Table 2. Key Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
Table 3. Ranking of Global Top Targeted Drugs for Multiple Myeloma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Immunomodulator
Table 6. Key Players of Proteasome Inhibitors
Table 7. Key Players of Histone Deacetylase Inhibitors (HDACI)
Table 8. Key Players of Monoclonal Antibody
Table 9. Key Players of Other
Table 10. COVID-19 Impact Global Market: (Four Targeted Drugs for Multiple Myeloma Market Size Forecast Scenarios)
Table 11. Opportunities and Trends for Targeted Drugs for Multiple Myeloma Players in the COVID-19 Landscape
Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 13. Key Regions/Countries Measures against Covid-19 Impact
Table 14. Proposal for Targeted Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
Table 15. Global Targeted Drugs for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 16. Global Targeted Drugs for Multiple Myeloma Market Size by Regions (US$ Million): 2020 VS 2026
Table 17. Global Targeted Drugs for Multiple Myeloma Market Size by Regions (2015-2020) (US$ Million)
Table 18. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2015-2020)
Table 19. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 20. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
Table 21. Market Top Trends
Table 22. Key Drivers: Impact Analysis
Table 23. Key Challenges
Table 24. Targeted Drugs for Multiple Myeloma Market Growth Strategy
Table 25. Main Points Interviewed from Key Targeted Drugs for Multiple Myeloma Players
Table 26. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2015-2020) (Million US$)
Table 27. Global Targeted Drugs for Multiple Myeloma Market Share by Players (2015-2020)
Table 28. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019)
Table 29. Global Targeted Drugs for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
Table 30. Key Players Headquarters and Area Served
Table 31. Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
Table 32. Date of Enter into Targeted Drugs for Multiple Myeloma Market
Table 33. Mergers & Acquisitions, Expansion Plans
Table 34. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 35. Global Targeted Drugs for Multiple Myeloma Market Size Share by Type (2015-2020)
Table 36. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2021-2026)
Table 37. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application (2015-2020)
Table 38. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 39. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application (2021-2026)
Table 40. North America Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 41. North America Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 42. North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 43. North America Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 44. North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 45. North America Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 46. Europe Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 47. Europe Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 48. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 49. Europe Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 50. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 51. Europe Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 52. China Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 53. China Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 54. China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 55. China Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 56. China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 57. China Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 58. Japan Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 59. Japan Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 60. Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 61. Japan Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 62. Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 63. Japan Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 64. Southeast Asia Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 65. Southeast Asia Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 67. Southeast Asia Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 68. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 69. Southeast Asia Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 70. India Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 71. India Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 72. India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 73. India Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 74. India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 75. India Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 76. Central & South America Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 77. Central & South America Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
Table 78. Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 79. Central & South America Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 80. Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 81. Central & South America Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 82. Celgene Company Details
Table 83. Celgene Business Overview
Table 84. Celgene Product
Table 85. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 86. Celgene Recent Development
Table 87. Exova Company Details
Table 88. Exova Business Overview
Table 89. Exova Product
Table 90. Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 91. Exova Recent Development
Table 92. Natco Pharma Company Details
Table 93. Natco Pharma Business Overview
Table 94. Natco Pharma Product
Table 95. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 96. Natco Pharma Recent Development
Table 97. Intas Pharmaceuticals Company Details
Table 98. Intas Pharmaceuticals Business Overview
Table 99. Intas Pharmaceuticals Product
Table 100. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 101. Intas Pharmaceuticals Recent Development
Table 102. Indiabulls Pharmaceutical Company Details
Table 103. Indiabulls Pharmaceutical Business Overview
Table 104. Indiabulls Pharmaceutical Product
Table 105. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 106. Indiabulls Pharmaceutical Recent Development
Table 107. Cipla Company Details
Table 108. Cipla Business Overview
Table 109. Cipla Product
Table 110. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 111. Cipla Recent Development
Table 112. Glenmark Pharmaceuticals Company Details
Table 113. Glenmark Pharmaceuticals Business Overview
Table 114. Glenmark Pharmaceuticals Product
Table 115. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 116. Glenmark Pharmaceuticals Recent Development
Table 117. Dr Reddy's Laboratories Business Overview
Table 118. Dr Reddy's Laboratories Product
Table 119. Dr Reddy's Laboratories Company Details
Table 120. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 121. Dr Reddy's Laboratories Recent Development
Table 122. Qilu Pharmaceutical Company Details
Table 123. Qilu Pharmaceutical Business Overview
Table 124. Qilu Pharmaceutical Product
Table 125. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 126. Qilu Pharmaceutical Recent Development
Table 127. Chia Tai-Tianqing Company Details
Table 128. Chia Tai-Tianqing Business Overview
Table 129. Chia Tai-Tianqing Product
Table 130. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 131. Chia Tai-Tianqing Recent Development
Table 132. Hanson Pharm Company Details
Table 133. Hanson Pharm Business Overview
Table 134. Hanson Pharm Product
Table 135. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 136. Hanson Pharm Recent Development
Table 137. Meidakang Huakang Pharmaceutical Company Details
Table 138. Meidakang Huakang Pharmaceutical Business Overview
Table 139. Meidakang Huakang Pharmaceutical Product
Table 140. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 141. Meidakang Huakang Pharmaceutical Recent Development
Table 142. Shandong Kongfu Pharmaceutical Company Details
Table 143. Shandong Kongfu Pharmaceutical Business Overview
Table 144. Shandong Kongfu Pharmaceutical Product
Table 145. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 146. Shandong Kongfu Pharmaceutical Recent Development
Table 147. J&J Company Details
Table 148. J&J Business Overview
Table 149. J&J Product
Table 150. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 151. J&J Recent Development
Table 152. Takeda Company Details
Table 153. Takeda Business Overview
Table 154. Takeda Product
Table 155. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 156. Takeda Recent Development
Table 157. Amgen Company Details
Table 158. Amgen Business Overview
Table 159. Amgen Product
Table 160. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 161. Amgen Recent Development
Table 162. Bristol Myers Squibb Company Details
Table 163. Bristol Myers Squibb Business Overview
Table 164. Bristol Myers Squibb Product
Table 165. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 166. Bristol Myers Squibb Recent Development
Table 167. Abbvie Company Details
Table 168. Abbvie Business Overview
Table 169. Abbvie Product
Table 170. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 171. Abbvie Recent Development
Table 172. Seattle Genetics Company Details
Table 173. Seattle Genetics Business Overview
Table 174. Seattle Genetics Product
Table 175. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 176. Seattle Genetics Recent Development
Table 177. Karyopharm Therapeutics Company Details
Table 178. Karyopharm Therapeutics Business Overview
Table 179. Karyopharm Therapeutics Product
Table 180. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 181. Karyopharm Therapeutics Recent Development
Table 182. PDL BioPharma Company Details
Table 183. PDL BioPharma Business Overview
Table 184. PDL BioPharma Product
Table 185. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 186. PDL BioPharma Recent Development
Table 187. Roche Company Details
Table 188. Roche Business Overview
Table 189. Roche Product
Table 190. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 191. Roche Recent Development
Table 192. Sumitomo Company Details
Table 193. Sumitomo Business Overview
Table 194. Sumitomo Product
Table 195. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 196. Sumitomo Recent Development
Table 197. Merck Company Details
Table 198. Merck Business Overview
Table 199. Merck Product
Table 200. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 201. Merck Recent Development
Table 202. Biogen Company Details
Table 203. Biogen Business Overview
Table 204. Biogen Product
Table 205. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 206. Biogen Recent Development
Table 207. Schering-Plough Company Details
Table 208. Schering-Plough Business Overview
Table 209. Schering-Plough Product
Table 210. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 211. Schering-Plough Recent Development
Table 212. Glaxo Company Details
Table 213. Glaxo Business Overview
Table 214. Glaxo Product
Table 215. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 216. Glaxo Recent Development
Table 217. Chiron Company Details
Table 218. Chiron Business Overview
Table 219. Chiron Product
Table 220. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 221. Chiron Recent Development
Table 222. Research Programs/Design for This Report
Table 223. Key Data Information from Secondary Sources
Table 224. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Targeted Drugs for Multiple Myeloma Market Share by Type: 2020 VS 2026
Figure 2. Immunomodulator Features
Figure 3. Proteasome Inhibitors Features
Figure 4. Histone Deacetylase Inhibitors (HDACI) Features
Figure 5. Monoclonal Antibody Features
Figure 6. Other Features
Figure 7. Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Drug Center Case Studies
Figure 10. Clinic Case Studies
Figure 11. Other Case Studies
Figure 12. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 13. Global Targeted Drugs for Multiple Myeloma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Targeted Drugs for Multiple Myeloma Market Share by Regions: 2020 VS 2026
Figure 15. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Targeted Drugs for Multiple Myeloma Market Share by Players in 2019
Figure 18. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2019
Figure 20. North America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Celgene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 29. Exova Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 31. Natco Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 33. Intas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 35. Indiabulls Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 37. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 39. Glenmark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 41. Dr Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 43. Qilu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 45. Chia Tai-Tianqing Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 47. Hanson Pharm Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 49. Meidakang Huakang Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 51. Shandong Kongfu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 53. J&J Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 55. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 57. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 59. Bristol Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 61. Abbvie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 63. Seattle Genetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 65. Karyopharm Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Figure 1. Global Targeted Drugs for Multiple Myeloma Market Share by Type: 2020 VS 2026
Figure 2. Immunomodulator Features
Figure 3. Proteasome Inhibitors Features
Figure 4. Histone Deacetylase Inhibitors (HDACI) Features
Figure 5. Monoclonal Antibody Features
Figure 6. Other Features
Figure 7. Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Drug Center Case Studies
Figure 10. Clinic Case Studies
Figure 11. Other Case Studies
Figure 12. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 13. Global Targeted Drugs for Multiple Myeloma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Targeted Drugs for Multiple Myeloma Market Share by Regions: 2020 VS 2026
Figure 15. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Targeted Drugs for Multiple Myeloma Market Share by Players in 2019
Figure 18. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2019
Figure 20. North America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Celgene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 29. Exova Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 31. Natco Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 33. Intas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 35. Indiabulls Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 37. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 39. Glenmark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 41. Dr Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 43. Qilu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 45. Chia Tai-Tianqing Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 47. Hanson Pharm Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 49. Meidakang Huakang Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 51. Shandong Kongfu Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 53. J&J Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 55. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 57. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 59. Bristol Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 61. Abbvie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 63. Seattle Genetics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 65. Karyopharm Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed